Zhejiang Arthur Pharmaceutical Co., Ltd.

Main study purpose: According to the relevant provisions of bioequivalence test, the ezetimibe simvastatin tablets (trade name: Baozhineng, specification: ezetimibe 10mg, simvastatin 20mg) of N.V.Organon (The Netherlands) as the licensee were selected as the reference preparation, and the test preparation ezetimibe simvastatin tablets (specification: ezetimibe 10mg, simvastatin 20mg) provided by Zhejiang Arthur Pharmaceutical Co., Ltd. were subjected to fasting and postprandial human bioequivalence test to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation ezetimibe simvastatin tablets (specification: ezetimibe 10mg, simvastatin 20mg) and the reference preparation ezetimibe simvastatin tablets (trade name: Baozhineng, specification: ezetimibe 10mg, simvastatin 20mg) by healthy volunteers.

Main research purpose: According to the relevant provisions of bioequivalence test, exemestane tablets (trade name: Arnoxin®, specification: 25mg) with Pfizer Italia s.r.l. as the licensee were selected as the reference preparation, and the test preparation exemestane tablets (specification: 25mg) produced by Lianyungang Jerry Pharmaceutical Co., Ltd. and licensed by Zhejiang Arthur Pharmaceutical Co., Ltd. were tested in human body under fasting and postprandial administration conditions, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation exemestane tablets (specification: 25mg) and the reference preparation exemestane tablets (trade name: Arnoxin®, specification: 25mg) by healthy subjects.